Document And Entity Information
Document And Entity Information | 6 Months Ended |
Jun. 30, 2023 | |
Document Information Line Items | |
Entity Registrant Name | Kamada Ltd |
Document Type | 6-K |
Current Fiscal Year End Date | --12-31 |
Amendment Flag | false |
Entity Central Index Key | 0001567529 |
Document Period End Date | Jun. 30, 2023 |
Document Fiscal Year Focus | 2023 |
Document Fiscal Period Focus | Q2 |
Entity File Number | 001-35948 |
Consolidated Statements of Fina
Consolidated Statements of Financial Position - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2022 |
Current Assets | |||
Cash and cash equivalents | $ 21,788 | $ 34,258 | $ 29,933 |
Trade receivables, net | 24,581 | 27,252 | 17,738 |
Other accounts receivables | 3,077 | 8,710 | 6,410 |
Inventories | 80,237 | 68,785 | 64,520 |
Total Current Assets | 129,683 | 139,005 | 118,601 |
Non-Current Assets | |||
Property, plant and equipment, net | 26,936 | 26,157 | 25,914 |
Right-of-use assets | 5,517 | 2,568 | 2,810 |
Intangible assets, Goodwill and other long-term assets | 143,986 | 147,072 | 150,449 |
Contract assets | 8,267 | 7,577 | 6,361 |
Total Non-Current Assets | 184,706 | 183,374 | 185,534 |
Total Assets | 314,389 | 322,379 | 304,135 |
Current Liabilities | |||
Current maturities of bank loans | 4,444 | 4,444 | 4,449 |
Current maturities of lease liabilities | 1,063 | 1,016 | 1,010 |
Current maturities of other long term liabilities | 25,077 | 29,708 | 20,117 |
Trade payables | 27,969 | 32,917 | 17,954 |
Other accounts payables | 7,235 | 7,585 | 6,110 |
Deferred revenues | 38 | 35 | 40 |
Total Current Liabilities | 65,826 | 75,705 | 49,680 |
Non-Current Liabilities | |||
Bank loans | 10,741 | 12,963 | 15,185 |
Lease liabilities | 4,972 | 2,177 | 2,492 |
Contingent consideration | 19,028 | 17,534 | 23,121 |
Other long-term liabilities | 36,514 | 37,308 | 41,304 |
Deferred revenues | 0 | 15 | |
Employee benefit liabilities, net | 556 | 672 | 764 |
Total Non-Current Liabilities | 71,811 | 70,654 | 82,881 |
Shareholder’s Equity | |||
Ordinary shares | 11,737 | 11,734 | 11,731 |
Additional paid in capital net | 210,727 | 210,495 | 210,319 |
Capital reserve due to translation to presentation currency | (3,490) | (3,490) | (3,490) |
Capital reserve from hedges | (67) | (88) | (442) |
Capital reserve from share-based payments | 5,902 | 5,505 | 5,097 |
Capital reserve from employee benefits | 424 | 348 | 271 |
Accumulated deficit | (48,481) | (48,484) | (51,912) |
Total Shareholder’s Equity | 176,752 | 176,020 | 171,574 |
Total Liabilities and Shareholder’s Equity | $ 314,389 | $ 322,379 | $ 304,135 |
Consolidated Statements of Prof
Consolidated Statements of Profit or Loss and Other Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Revenues from proprietary products | $ 30,940 | $ 18,607 | $ 55,001 | $ 41,618 | $ 102,598 |
Revenues from distribution | 6,503 | 4,983 | 13,152 | 10,065 | 26,741 |
Total revenues | 37,443 | 23,590 | 68,153 | 51,683 | 129,339 |
Cost of revenues from proprietary products | 17,192 | 12,256 | 30,416 | 24,705 | 58,229 |
Cost of revenues from distribution | 5,815 | 4,094 | 11,462 | 8,436 | 24,407 |
Total cost of revenues | 23,007 | 16,350 | 41,878 | 33,141 | 82,636 |
Gross profit | 14,436 | 7,240 | 26,275 | 18,542 | 46,703 |
Research and development expenses | 4,283 | 2,643 | 7,514 | 7,063 | 13,172 |
Selling and marketing expenses | 3,940 | 3,271 | 7,862 | 6,592 | 15,284 |
General and administrative expenses | 3,484 | 3,311 | 6,902 | 6,316 | 12,803 |
Other expenses | 98 | 309 | 1,077 | 619 | 912 |
Operating income (loss) | 2,631 | (2,294) | 2,920 | (2,048) | 4,532 |
Financial income | 1 | 25 | 3 | 91 | |
Income (expenses) in respect of currency exchange differences and derivatives instruments, net | 22 | 424 | 173 | 593 | 298 |
Financial Income (expense) in respect of contingent consideration and other long- term liabilities. | (309) | (1,865) | (2,070) | (3,875) | (6,266) |
Financial expenses | (439) | (178) | (939) | (372) | (914) |
Income (expense) before tax on income | 1,905 | (3,912) | 109 | (5,699) | (2,259) |
Taxes on income | 93 | 9 | 106 | 50 | 62 |
Net Income (loss) | 1,812 | (3,921) | 3 | (5,749) | (2,321) |
Gain (loss) on cash flow hedges | (88) | (676) | (244) | (784) | (776) |
Net amounts transferred to the statement of profit or loss for cash flow hedges | 120 | 222 | 265 | 288 | 634 |
Remeasurement gain (loss) from defined benefit plan | (115) | 420 | 76 | 420 | 497 |
Tax effect | |||||
Total comprehensive income (loss) | $ 1,729 | $ (3,955) | $ 100 | $ (5,825) | $ (1,966) |
Basic net earnings per share (in Dollars per share) | $ 0.04 | $ (0.09) | $ 0 | $ (0.13) | $ (0.05) |
Diluted net earnings per share (in Dollars per share) | $ 0.04 | $ (0.09) | $ 0 | $ (0.13) | $ (0.05) |
Consolidated Statements of Chan
Consolidated Statements of Changes in Equity - USD ($) $ in Thousands | Share capital | Additional paid in capital | Capital reserve due to translation to presentation currency | Capital reserve from hedges | Capital reserve from sharebased payments | Capital reserve from employee benefits | Accumulated deficit | Total |
Balance at Dec. 31, 2021 | $ 11,725 | $ 210,204 | $ (3,490) | $ 54 | $ 4,643 | $ (149) | $ (46,163) | $ 176,824 |
Net income | (5,749) | (5,749) | ||||||
Other comprehensive income (loss) | (496) | 420 | (76) | |||||
Tax effect | ||||||||
Total comprehensive income (loss) | (496) | 420 | (5,749) | (5,825) | ||||
Exercise and forfeiture of share-based payment into shares | 6 | 115 | (115) | 6 | ||||
Cost of share-based payment | 504 | 504 | ||||||
Balance at Jun. 30, 2022 | 11,731 | 210,319 | (3,490) | (442) | 5,097 | 271 | (51,912) | 171,574 |
Balance at Dec. 31, 2021 | 11,725 | 210,204 | (3,490) | 54 | 4,643 | (149) | (46,163) | 176,824 |
Net income | (2,321) | (2,321) | ||||||
Other comprehensive income (loss) | (142) | 497 | 355 | |||||
Tax effect | ||||||||
Total comprehensive income (loss) | (142) | 497 | (2,321) | (1,966) | ||||
Exercise and forfeiture of share-based payment into shares | 9 | 291 | (291) | 9 | ||||
Cost of share-based payment | 1,153 | 1,153 | ||||||
Balance at Dec. 31, 2022 | 11,734 | 210,495 | (3,490) | (88) | 5,505 | 348 | (48,484) | 176,020 |
Balance at Mar. 31, 2022 | 11,728 | 210,269 | (3,490) | 12 | 4,771 | (149) | (47,991) | 175,150 |
Net income | (3,921) | (3,921) | ||||||
Other comprehensive income (loss) | (454) | 420 | (34) | |||||
Tax effect | ||||||||
Total comprehensive income (loss) | (454) | 420 | (3,921) | (3,955) | ||||
Exercise and forfeiture of share-based payment into shares | 3 | 50 | (50) | 3 | ||||
Cost of share-based payment | 376 | 376 | ||||||
Balance at Jun. 30, 2022 | 11,731 | 210,319 | (3,490) | (442) | 5,097 | 271 | (51,912) | 171,574 |
Balance at Dec. 31, 2022 | 11,734 | 210,495 | (3,490) | (88) | 5,505 | 348 | (48,484) | 176,020 |
Net income | 3 | 3 | ||||||
Other comprehensive income (loss) | 21 | 76 | 97 | |||||
Tax effect | ||||||||
Total comprehensive income (loss) | 21 | 76 | 3 | 100 | ||||
Exercise and forfeiture of share-based payment into shares | 3 | 232 | (232) | 3 | ||||
Cost of share-based payment | 629 | 629 | ||||||
Balance at Jun. 30, 2023 | 11,737 | 210,727 | (3,490) | (67) | 5,902 | 424 | (48,481) | 176,752 |
Balance at Mar. 31, 2023 | 11,736 | 210,665 | (3,490) | (99) | 5,750 | 539 | (50,293) | 174,808 |
Net income | 1,812 | 1,812 | ||||||
Other comprehensive income (loss) | 32 | (115) | (83) | |||||
Tax effect | ||||||||
Total comprehensive income (loss) | 32 | (115) | 1,812 | 1,729 | ||||
Exercise and forfeiture of share-based payment into shares | 1 | 62 | (62) | 1 | ||||
Cost of share-based payment | 214 | 214 | ||||||
Balance at Jun. 30, 2023 | $ 11,737 | $ 210,727 | $ (3,490) | $ (67) | $ 5,902 | $ 424 | $ (48,481) | $ 176,752 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Cash Flows from Operating Activities | |||||
Net income (loss) | $ 1,812 | $ (3,921) | $ 3 | $ (5,749) | $ (2,321) |
Adjustments to the profit or loss items: | |||||
Depreciation and impairment | 3,204 | 3,061 | 6,327 | 6,088 | 12,155 |
Financial expenses (income), net | 726 | 1,618 | 2,811 | 3,651 | 6,791 |
Cost of share-based payment | 214 | 376 | 629 | 569 | 1,153 |
Taxes on income | 93 | 9 | 106 | 50 | 62 |
Loss (gain) from sale of property and equipment | (5) | ||||
Change in employee benefit liabilities, net | (32) | (84) | (40) | (96) | (111) |
Adjustments to the profit or loss items | 4,205 | 4,980 | 9,828 | 10,262 | 20,050 |
Changes in asset and liability items: | |||||
Decrease (increase) in trade receivables, net | (3,610) | 3,610 | 2,696 | 17,102 | 7,603 |
Decrease (increase) in other accounts receivables | 177 | 1,484 | 1,539 | 2,073 | (578) |
Decrease (increase) in inventories | (482) | 241 | (11,452) | 2,903 | (1,361) |
Decrease (increase) in deferred expenses | (512) | (374) | 3,042 | (484) | (1,340) |
Increase (decrease) in trade payables | 1,276 | 5,806 | (5,436) | (7,843) | 7,055 |
Increase (decrease) in other accounts payables | (170) | (745) | (408) | (1,517) | 290 |
Decrease in deferred revenues | (381) | 3 | (20) | ||
Total Changes in asset and liability | (3,702) | 10,022 | (10,016) | 12,234 | 11,649 |
Cash received (paid) during the period for: | |||||
Interest paid | (403) | (186) | (744) | (380) | (853) |
Interest received | 0 | 1 | 25 | 3 | 97 |
Taxes paid | (94) | (9) | (112) | (18) | (36) |
Cash received (paid) during the year | (497) | (194) | (831) | (395) | (792) |
Net cash provided by (used in) operating activities | 1,818 | 10,887 | (1,016) | 16,352 | 28,586 |
Cash Flows from Investing Activities | |||||
Purchase of property and equipment and intangible assets | (1,048) | (678) | (2,147) | (1,191) | (3,784) |
Proceeds from sale of property and equipment | 6 | ||||
Business combination | |||||
Net cash provided by (used in) investing activities | (1,048) | (678) | (2,141) | (1,191) | (3,784) |
Cash Flows from Financing Activities | |||||
Proceeds from exercise of share base payments | 2 | 3 | 3 | 6 | 9 |
Receipt of long-term loans | |||||
Repayment of lease liabilities | (246) | (278) | (517) | (573) | (1,098) |
Repayment of long-term loans | (1,111) | (385) | (2,222) | (401) | (2,628) |
Repayment of other long-term liabilities | (4,500) | (1,743) | (6,000) | (3,243) | (5,626) |
Net cash provided by (used in) financing activities | (5,855) | (2,403) | (8,736) | (4,211) | (9,343) |
Exchange differences on balances of cash and cash equivalent | (248) | 160 | (577) | 396 | 212 |
Increase (decrease) in cash and cash equivalents | (5,333) | 7,966 | (12,470) | 11,346 | 15,671 |
Cash and cash equivalents at the beginning of the period | 27,121 | 21,967 | 34,258 | 18,587 | 18,587 |
Cash and cash equivalents at the end of the period | 21,788 | 29,933 | 21,788 | 29,933 | 34,258 |
Significant non-cash transactions | |||||
Right-of-use asset recognized with corresponding lease liability | 5 | 121 | 3,585 | 296 | 551 |
Purchase of property and equipment and Intangible assets | $ 840 | $ 775 | $ 840 | $ 775 | $ 618 |
General
General | 6 Months Ended |
Jun. 30, 2023 | |
General [Abstract] | |
General | Note 1:- General General description of the Company and its activity Kamada Ltd. (the “Company”) is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products CYTOGAM®, KEDRAB®, WINRHO SDF®, VARIZIG®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D) ® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, Middle East and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During recent years added eleven biosimilar products to its Israeli distribution portfolio, which, subject to European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D). In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. In November 2021, the Company acquired CYTOGAM, WINRHO SDF, VARIZIG and HEPGAM B from Saol Therapeutics Ltd. (“Saol”). The acquisition of this portfolio furthered the Company’s core objective to become a fully integrated specialty plasma company with strong commercial capabilities in the U.S. market, as well as to expand to new markets, mainly in the Middle East/North Africa region, and to broaden the Company’s portfolio offering in existing markets. The Company’s wholly owned U.S. subsidiary, Kamada Inc., is responsible for the commercialization of the four products in the U.S. market, including direct sales to wholesalers and local distributers. Refer to Note 5 in our annual Financial report for further details on this acquisition. |
Significant Accounting Policies
Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2023 | |
Significant Accounting Policies [Abstract] | |
Significant Accounting Policies | Note 2:- Significant Accounting Policies a. Basis of preparation of the interim consolidated financial statements: The interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, “Interim Financial Reporting”. b. Implementation of new accounting standards: Amendment to IAS 1, Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current Non-Current Liabilities with Covenants The Amendment, together with the subsequent amendment to IAS 1 (see hereunder) replaces certain requirements for classifying liabilities as current or non-current. According to the Amendment, a liability will be classified as non-current when the entity has the right to defer settlement for at least 12 months after the reporting period, and it “has substance” and is in existence at the end of the reporting period. According to the subsequent amendment, as published in October 2022, covenants with which the entity must comply after the reporting date do not affect classification of the liability as current or non-current. Additionally, the subsequent amendment adds disclosure requirements for liabilities subject to covenants within 12 months after the reporting date, such as disclosure regarding the nature of the covenants, the date they need to be complied with and facts and circumstances that indicate the entity may have difficulty complying with the covenants. Furthermore, the Amendment clarifies that the conversion option of a liability will affect its classification as current or non-current, other than when the conversion option is recognized as equity. The Amendment and subsequent amendment are effective for reporting periods beginning on or after January 1, 2024 with earlier application being permitted. The Amendment and subsequent amendment are applicable retrospectively, including an amendment to comparative data. The Company believes that the adoption of the Amendment will not have an effect on its financial statements. |
Significant Events in the Repor
Significant Events in the Reporting Period | 6 Months Ended |
Jun. 30, 2023 | |
Significant Events in the Reporting Period [Abstract] | |
Significant events in the reporting period | Note 3:- Significant events in the reporting period Grant of options to the purchase ordinary shares of the Company to employees, executive officers. On February 27, 2023, the Company’s Board of Directors approved the grant of options to purchase up to 147,000 options to purchase ordinary shares of the Company under the 2011 Plan and the US Appendix. The Company granted, out of the above mentioned, to employees and executive officers the following: Under the Israeli Share Option Plan: - On February 27, 2023, 60,331 options to purchase the ordinary shares of the Company, at an exercise price of NIS 16.53 (USD 4.50) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated at $108 thousands. - On March 01, 2023 3,333 options to purchase ordinary shares of the Company, at an exercise price of NIS 16.63 (USD 4.57) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $5.7 thousands. - On March 02, 2023 40,000 options to purchase ordinary shares of the Company, at an exercise price of NIS 16.76 (USD 4.60) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $71 thousands. - On April 23, 2023 40,000 options to purchase ordinary shares of the Company, at an exercise price of NIS 17.67 (USD 4.83) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $65 thousands. Under the US Appendix: - On February 27, 2023 3,333 options to purchase the ordinary shares of the Company, at an exercise price of USD 4.57 per share. The fair value of the options was estimated on the date of grant was estimated at $5.80 thousands. On May 28, 2023, the Company’s Board of Directors approved the grant of 90,000 options to purchase ordinary shares of the Company, under the Israeli Share Option Plan, at an exercise price of NIS 19.46 (USD 5.25) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $217 thousands. |
Operating Segments
Operating Segments | 6 Months Ended |
Jun. 30, 2023 | |
Operating Segments [Abstract] | |
Operating Segments | Note 4:- Operating Segments a. General: The company has two operating segments, as follows: Proprietary Products - Development, manufacturing, sales and distribution of proprietary plasma-derived protein therapeutics. Distribution - Distribute imported drug products in Israel, which are manufactured by third parties. b. Reporting on operating segments: Proprietary Distribution Total U.S Dollars in thousands Unaudited Six months period ended June 30, 2023 Revenues $ 55,001 $ 13,152 $ 68,153 Gross profit $ 24,585 $ 1,690 $ 26,275 Unallocated corporate expenses (23,355 ) Finance expenses, net (2,811 ) Income before taxes on income $ 109 Proprietary Distribution Total U.S Dollars in thousands Unaudited Six months period ended June 30, 2022 Revenues $ 41,618 $ 10,065 $ 51,683 Gross profit $ 16,913 $ 1,629 $ 18,542 Unallocated corporate expenses (20,590 ) Finance expenses, net (3,651 ) Income before taxes on income $ (5,699 ) Proprietary Distribution Total U.S Dollars in thousands Unaudited Three months period ended June 30, 2023 Revenues $ 34,940 $ 6,503 $ 37,443 Gross profit $ 13,748 $ 688 $ 14,436 Unallocated corporate expenses (11,805 ) Finance expenses, net (726 ) Income before taxes on income $ 1,905 Proprietary Distribution Total U.S Dollars in thousands Unaudited Three months period ended June 30, 2022 Revenues $ 18,607 $ 4,983 $ 23,590 Gross profit $ 6,351 $ 899 $ 7,240 Unallocated corporate expenses (9,534 ) Finance expenses, net (1,618 ) Income before taxes on income $ (3,912 ) b. Reporting on operating segments: Proprietary Distribution Total U.S Dollars in thousands Audited Year Ended December 31, 2022 Revenues $ 102,598 $ 26,741 $ 129,339 Gross profit $ 44,369 $ 2,334 $ 46,703 Unallocated corporate expenses (42,171 ) Finance expenses, net (6,791 ) Income before taxes on income $ (2,259 ) c. Reporting on operating segments by geographic region: Six months period ended Proprietary Distribution Total U.S Dollars in thousands Unaudited Geographical markets U.S.A and North America $ 36,856 $ - $ 36,856 Israel 2,101 13,152 15,252 Europe 3,550 - 3,550 Latin America 9,931 - 9,931 Asia 2,480 - 2,480 Others 83 - 83 $ 55,001 $ 13,152 $ 68,153 c. Reporting on operating segments by geographic region: Six months period ended Proprietary Distribution Total U.S Dollars in thousands Unaudited Geographical markets U.S.A and North America. $ 28,562 $ - $ 28,562 Israel 2,254 10,065 12,319 Europe 5,149 - 5,149 Latin America 3,526 - 3,526 Asia 1,760 - 1,760 Others 367 - 367 $ 41,618 $ 10,065 $ 51,683 Three months period ended Proprietary Distribution Total U.S Dollars in thousands Unaudited Geographical markets U.S.A and North America. $ 20,026 $ - $ 20,026 Israel 1,107 6,503 7,610 Europe 216 - 216 Latin America 8,615 - 8,615 Asia 930 - 930 Others 46 - 46 $ 30,940 $ 6,503 $ 37,443 Three months period ended Proprietary Distribution Total U.S Dollars in thousands Unaudited Geographical markets U.S.A and North America. $ 11,611 $ - $ 11,611 Israel 627 4,983 5,610 Europe 4,097 - 4,097 Latin America 1,496 - 1,496 Asia 776 - 776 Others - - - $ 18,607 $ 4,983 $ 23,590 Year ended December 31, 2022 Proprietary Distribution Total U.S Dollars in thousands Audited Geographical markets U.S.A and North America $ 75,851 $ - $ 75,851 Israel 5,290 26,741 32,031 Europe 5,277 - 5,277 Latin America 11,293 - 11,293 Asia 4,581 - 4,581 Others 305 - 305 $ 102,597 $ 26,741 $ 129,338 |
Financial Instruments
Financial Instruments | 6 Months Ended |
Jun. 30, 2023 | |
Financial Instruments [Abstract] | |
Financial Instruments | Note 5:- Financial Instruments a. Classification of financial instruments by fair value hierarchy Financial assets (liabilities) measured at fair value Level 1 Level 2 Level 3 U.S Dollars in thousands June 30, 2023 Derivatives instruments $ - $ (72 ) $ - Contingent consideration - - (21,712 ) June 30, 2022 Derivatives instruments (437 ) Contingent consideration $ - $ $ (23,121 ) December 31, 2022 Derivatives instruments $ - $ (92 ) $ - Contingent consideration $ - $ - $ (23,534 ) During the six months ended on June 30, 2023 there were no transfers due to the fair value measurement of any financial instrument from Level 1 to Level 2, and furthermore, there were no transfers to or from Level 3 due to the fair value measurement of any financial instrument. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 6 Months Ended |
Jun. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of preparation of the interim consolidated financial statements | a. Basis of preparation of the interim consolidated financial statements: The interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, “Interim Financial Reporting”. |
Implementation of new accounting standards | b. Implementation of new accounting standards: Amendment to IAS 1, Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current Non-Current Liabilities with Covenants The Amendment, together with the subsequent amendment to IAS 1 (see hereunder) replaces certain requirements for classifying liabilities as current or non-current. According to the Amendment, a liability will be classified as non-current when the entity has the right to defer settlement for at least 12 months after the reporting period, and it “has substance” and is in existence at the end of the reporting period. According to the subsequent amendment, as published in October 2022, covenants with which the entity must comply after the reporting date do not affect classification of the liability as current or non-current. Additionally, the subsequent amendment adds disclosure requirements for liabilities subject to covenants within 12 months after the reporting date, such as disclosure regarding the nature of the covenants, the date they need to be complied with and facts and circumstances that indicate the entity may have difficulty complying with the covenants. Furthermore, the Amendment clarifies that the conversion option of a liability will affect its classification as current or non-current, other than when the conversion option is recognized as equity. The Amendment and subsequent amendment are effective for reporting periods beginning on or after January 1, 2024 with earlier application being permitted. The Amendment and subsequent amendment are applicable retrospectively, including an amendment to comparative data. The Company believes that the adoption of the Amendment will not have an effect on its financial statements. |
Operating Segments (Tables)
Operating Segments (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Operating Segments [Abstract] | |
Schedule of Reporting on Operating Segments Geographic Region | Proprietary Distribution Total U.S Dollars in thousands Unaudited Six months period ended June 30, 2023 Revenues $ 55,001 $ 13,152 $ 68,153 Gross profit $ 24,585 $ 1,690 $ 26,275 Unallocated corporate expenses (23,355 ) Finance expenses, net (2,811 ) Income before taxes on income $ 109 Proprietary Distribution Total U.S Dollars in thousands Unaudited Six months period ended June 30, 2022 Revenues $ 41,618 $ 10,065 $ 51,683 Gross profit $ 16,913 $ 1,629 $ 18,542 Unallocated corporate expenses (20,590 ) Finance expenses, net (3,651 ) Income before taxes on income $ (5,699 ) Proprietary Distribution Total U.S Dollars in thousands Unaudited Three months period ended June 30, 2023 Revenues $ 34,940 $ 6,503 $ 37,443 Gross profit $ 13,748 $ 688 $ 14,436 Unallocated corporate expenses (11,805 ) Finance expenses, net (726 ) Income before taxes on income $ 1,905 Proprietary Distribution Total U.S Dollars in thousands Unaudited Three months period ended June 30, 2022 Revenues $ 18,607 $ 4,983 $ 23,590 Gross profit $ 6,351 $ 899 $ 7,240 Unallocated corporate expenses (9,534 ) Finance expenses, net (1,618 ) Income before taxes on income $ (3,912 ) Proprietary Distribution Total U.S Dollars in thousands Audited Year Ended December 31, 2022 Revenues $ 102,598 $ 26,741 $ 129,339 Gross profit $ 44,369 $ 2,334 $ 46,703 Unallocated corporate expenses (42,171 ) Finance expenses, net (6,791 ) Income before taxes on income $ (2,259 ) |
Schedule of Reporting on Operating Segments Geographic Region | Six months period ended Proprietary Distribution Total U.S Dollars in thousands Unaudited Geographical markets U.S.A and North America $ 36,856 $ - $ 36,856 Israel 2,101 13,152 15,252 Europe 3,550 - 3,550 Latin America 9,931 - 9,931 Asia 2,480 - 2,480 Others 83 - 83 $ 55,001 $ 13,152 $ 68,153 Six months period ended Proprietary Distribution Total U.S Dollars in thousands Unaudited Geographical markets U.S.A and North America. $ 28,562 $ - $ 28,562 Israel 2,254 10,065 12,319 Europe 5,149 - 5,149 Latin America 3,526 - 3,526 Asia 1,760 - 1,760 Others 367 - 367 $ 41,618 $ 10,065 $ 51,683 Three months period ended Proprietary Distribution Total U.S Dollars in thousands Unaudited Geographical markets U.S.A and North America. $ 20,026 $ - $ 20,026 Israel 1,107 6,503 7,610 Europe 216 - 216 Latin America 8,615 - 8,615 Asia 930 - 930 Others 46 - 46 $ 30,940 $ 6,503 $ 37,443 Three months period ended Proprietary Distribution Total U.S Dollars in thousands Unaudited Geographical markets U.S.A and North America. $ 11,611 $ - $ 11,611 Israel 627 4,983 5,610 Europe 4,097 - 4,097 Latin America 1,496 - 1,496 Asia 776 - 776 Others - - - $ 18,607 $ 4,983 $ 23,590 Year ended December 31, 2022 Proprietary Distribution Total U.S Dollars in thousands Audited Geographical markets U.S.A and North America $ 75,851 $ - $ 75,851 Israel 5,290 26,741 32,031 Europe 5,277 - 5,277 Latin America 11,293 - 11,293 Asia 4,581 - 4,581 Others 305 - 305 $ 102,597 $ 26,741 $ 129,338 |
Financial Instruments (Tables)
Financial Instruments (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Financial Instruments [Abstract] | |
Schedule of Financial Assets (Liabilities) Measured at Fair Value | Level 1 Level 2 Level 3 U.S Dollars in thousands June 30, 2023 Derivatives instruments $ - $ (72 ) $ - Contingent consideration - - (21,712 ) June 30, 2022 Derivatives instruments (437 ) Contingent consideration $ - $ $ (23,121 ) December 31, 2022 Derivatives instruments $ - $ (92 ) $ - Contingent consideration $ - $ - $ (23,534 ) |
Significant Events in the Rep_2
Significant Events in the Reporting Period (Details) | May 28, 2023 USD ($) $ / shares | May 28, 2023 USD ($) ₪ / shares | Apr. 23, 2023 USD ($) $ / shares | Apr. 23, 2023 USD ($) ₪ / shares | Mar. 01, 2023 USD ($) $ / shares | Mar. 01, 2023 USD ($) ₪ / shares | Feb. 27, 2023 USD ($) $ / shares | Feb. 27, 2023 USD ($) ₪ / shares | Mar. 02, 2022 USD ($) $ / shares ₪ / shares |
Significant Events in the Reporting Period (Details) [Line Items] | |||||||||
Option granted | 3,333 | 3,333 | |||||||
Exercise price | $ / shares | $ 4.57 | ||||||||
Fair value of options (in Dollars) | $ | $ 5,800 | $ 5,800 | |||||||
Option [Member] | |||||||||
Significant Events in the Reporting Period (Details) [Line Items] | |||||||||
Option granted | 90,000 | 90,000 | 40,000 | 40,000 | 3,333 | 3,333 | 60,331 | 60,331 | 40,000 |
Exercise price | (per share) | $ 5.25 | ₪ 19.46 | $ 4.83 | ₪ 17.67 | $ 4.57 | ₪ 16.63 | $ 4.5 | $ 16.53 | ₪ 16.76 |
Fair value of options (in Dollars) | $ | $ 217,000 | ₪ 217,000 | $ 65,000 | ₪ 65,000 | $ 5,700 | ₪ 5,700 | $ 108,000 | $ 108,000 | ₪ 71,000 |
Exercise prices for share option (in Dollars per share) | $ / shares | ₪ 4.6 | ||||||||
Board of Directors [Member] | |||||||||
Significant Events in the Reporting Period (Details) [Line Items] | |||||||||
Option granted | 147,000 | 147,000 |
Operating Segments (Details) -
Operating Segments (Details) - Schedule of Reporting on Operating Segments - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Operating Segments (Details) - Schedule of Reporting on Operating Segments [Line Items] | |||||
Revenues | $ 37,443 | $ 23,590 | $ 68,153 | $ 51,683 | $ 129,339 |
Gross profit | 14,436 | 7,240 | 26,275 | 18,542 | 46,703 |
Unallocated corporate expenses | (11,805) | (9,534) | (23,355) | (20,590) | (42,171) |
Finance expenses, net | (726) | (1,618) | (2,811) | (3,651) | (6,791) |
Income before taxes on income | 1,905 | (3,912) | 109 | (5,699) | (2,259) |
Proprietary Products [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments [Line Items] | |||||
Revenues | 34,940 | 18,607 | 55,001 | 41,618 | 102,598 |
Gross profit | 13,748 | 6,351 | 24,585 | 16,913 | 44,369 |
Distribution [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments [Line Items] | |||||
Revenues | 6,503 | 4,983 | 13,152 | 10,065 | 26,741 |
Gross profit | $ 688 | $ 899 | $ 1,690 | $ 1,629 | $ 2,334 |
Operating Segments (Details) _2
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Total | $ 37,443 | $ 23,590 | $ 68,153 | $ 51,683 | $ 129,338 |
Proprietary Products [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Proprietary Products | 30,940 | 18,607 | 55,001 | 41,618 | 102,597 |
Distribution [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Distribution | 6,503 | 4,983 | 13,152 | 10,065 | 26,741 |
U.S.A and North America [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Total | 20,026 | 11,611 | 36,856 | 28,562 | 75,851 |
U.S.A and North America [Member] | Proprietary Products [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Proprietary Products | 20,026 | 11,611 | 36,856 | 28,562 | 75,851 |
U.S.A and North America [Member] | Distribution [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Distribution | |||||
Israel [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Total | 15,252 | ||||
Israel [Member] | Proprietary Products [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Proprietary Products | 2,101 | ||||
Israel [Member] | Distribution [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Distribution | 13,152 | ||||
Europe [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Total | 216 | 4,097 | 3,550 | 5,149 | 5,277 |
Europe [Member] | Proprietary Products [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Proprietary Products | 216 | 4,097 | 3,550 | 5,149 | 5,277 |
Europe [Member] | Distribution [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Distribution | |||||
Latin America [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Total | 8,615 | 1,496 | 9,931 | 3,526 | 11,293 |
Latin America [Member] | Proprietary Products [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Proprietary Products | 8,615 | 1,496 | 9,931 | 3,526 | 11,293 |
Latin America [Member] | Distribution [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Distribution | |||||
Asia [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Total | 930 | 776 | 2,480 | 1,760 | 4,581 |
Asia [Member] | Proprietary Products [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Proprietary Products | 930 | 776 | 2,480 | 1,760 | 4,581 |
Asia [Member] | Distribution [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Distribution | |||||
Others [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Total | 46 | 83 | 367 | 305 | |
Others [Member] | Proprietary Products [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Proprietary Products | 46 | 83 | 367 | 305 | |
Others [Member] | Distribution [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Distribution | |||||
Israel [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Total | 7,610 | 5,610 | 12,319 | 32,031 | |
Israel [Member] | Proprietary Products [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Proprietary Products | 1,107 | 627 | 2,254 | 5,290 | |
Israel [Member] | Distribution [Member] | |||||
Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region [Line Items] | |||||
Distribution | $ 6,503 | $ 4,983 | $ 10,065 | $ 26,741 |
Financial Instruments (Details)
Financial Instruments (Details) - Schedule of Financial Assets (Liabilities) Measured at Fair Value - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2022 |
Level 1 [Member] | |||
Financial Instruments (Details) - Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items] | |||
Derivatives instruments | |||
Contingent consideration | |||
Level 2 [Member] | |||
Financial Instruments (Details) - Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items] | |||
Derivatives instruments | (72) | (92) | (437) |
Contingent consideration | |||
Level 3 [Member] | |||
Financial Instruments (Details) - Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items] | |||
Derivatives instruments | |||
Contingent consideration | $ (21,712) | $ (23,534) | $ (23,121) |